Current perspectives on benefits and risks of hormone replacement therapy

American Journal of Obstetrics and Gynecology

Volumn 185, Issue 2 SUPPL., 2001, Pages

  Burkman, Ronald T ^a,b   Collins, John A ^c   Greene, Robert A ^d  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BAYSTATE MEDICAL CENTER   (United States)

^c MCMASTER UNIVERSITY   (Canada)

^d Specialty Care for Women   (United States)

Author keywords

Alzheimer's disease; Breast cancer; Cardiovascular disease; Colorectal cancer; Hormone replacement; Osteoporosis

Indexed keywords

ESTROGEN; GESTAGEN;

ALZHEIMER DISEASE; ARTICLE; BONE DENSITY; BREAST CANCER; CARDIOVASCULAR DISEASE; COLORECTAL CANCER; ESTROGEN THERAPY; HIP FRACTURE; HORMONE SUBSTITUTION; LIFE EXPECTANCY; MENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; QUALITY OF LIFE; RISK BENEFIT ANALYSIS;

EID: 0034876551     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1067/mob.2001.117414     Document Type: Article

References (74)

1. Confronting aging and disease: The role of HRT
2. Consensns development conference: Diagnosis, prophylaxis, and treatment of osteoporosis
3. Postmenopausal hormone therapy and the risk of colorectal cancer: A review and meta-analysis
4. Estrogen use, APOE, and cognitive decline: Evidence of gene-environment interaction
5. Estrogen and cerebral blood flow: A mechanism to explain the impact of estrogen on the incidence and treatment of Alzheimer's disease
6. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: Report from the National Osteoporosis Foundation
7. Are osteoporotic fractures due to osteoporosis? Impacts of a frailty pandemic in an aging world
8. Osteoporosis: Epidemiology, diagnosis, and treatment
9. Metabolic bone disease
10. Involutional osteoporosis
11. Treatment of postmenopausal osteoporosis
12. Low-dosage micronized 17β-estradiol prevents bone loss in postmenopausal women
13. Effects of hormone therapy on bone mineral density: Results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial
14. Treatment of postmenopausal osteoporosis with transdermal estrogen
15. The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women
16. Low-dose esterified estrogen therapy: Effects on bone, plasma estradiol concentrations, endometrium, and lipid levels
17. Effect of estrone sulfate on postmenopausal bone loss
18. Low and conventional dose transdermal oestradiol are equally effective at preventing bone loss in spine and femur at all post-menopausal ages
19. The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART Study): A randomized controlled trial
20. Estrogen: Prevendon and treatment of osteoporosis
21. Timing of postmenopausal estrogen for optimal bone mineral density: The Rancho Bernardo Study
22. Estrogen replacement therapy and colon cancer: A clinical review
23. Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women
24. Loss of estrogen inactivation in colonic cancer
25. Measurement of estrogen's effects on the brain using modern imaging techniques
26. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset
27. Human behavioral sex differences: A role for gonadal hormones during early development?
28. A PET study of Turner's Syndrome: Effects of sex steroids and the X chromosome on the brain
29. Sex differences in the functional organization of the brain for language
30. Effect of estrogen on regional cerebral blood flow in postmenopausal women
31. Cerebral blood flow
32. Estrogen and cerebral blood flow: A proposed mechanism to explain the observed benefit of estrogen replacement therapy on the prevention and treatment of Alzheimer's disease
33. Higher levels of plasma estradiol and testosterone in healthy elderly men compared with age-matched women may protect aspects of explicit memory
34. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: A randomized controlled trial
35. Apolipoprotein E polymorphism is associated with segment-specific extracranial carotid artery intima-media thickening
36. The role of APOE epsilon 4 in modulating effects of other risk factors for cognitive decline in elderly persons
37. Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50: The Framingham study
38. Rationale for hormone replacement therapy in atherosclerosis prevention
39. Coronary heart disease and its risk factors among women in the Framingham Study
40. Effects on the cardiovascular system: Basic aspects
41. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial
42. A novel intermittent regimen of norgestimate to preserve the beneficial effects of 17β-estradiol on lipid and lipoprotein profiles
43. Effects on serum lipid profiles of continuous 17β-estradiol, intermittent norgestimate regimens versus continuous combined 17β-estradiol/norethisterone acetate hormone replacement therapy
44. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
45. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis
46. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens
47. Risk of venous thromboembolism in users of hormone replacement therapy
48. Prospective study of exogenous hormones and risk of pulmonary embolism in women
49. Postmenopausal oestrogen treatment and stroke: A prospective study
50. Hormone replacement therapy and the risk of stroke: Follow-up of a population-based cohort in Sweden
51. Decreased risk of stroke among postmenopausal hormone users: Results from a national cohort
52. Postmenopausal estrogen therapy and cardiovascular disease: Ten-year follow-up from the Nurses' Health Study
53. Hormone replacement therapy and breast cancer: What is happening?
54. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer
55. Hormone replacement therapy and risk of breast cancer with a favorable histology: Results of the Iowa Women's Health Study
56. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk
57. Effect of hormone replacement therapy on breast cancer risk: Estrogen versus estrogen plus progestin
58. The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer
59. Estrogen replacement therapy and breast cancer survival in a large screening study
60. Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women
61. Effects of estrogen on urethral function in women with urinary incontinence
62. Post-menopausal hormone use and tooth loss: A prospective study
63. The benefits of estrogen replacement therapy on oral health: The Leisure World cohort
64. Effect of postmenopausal hormone therapy on body weight and waist and hip girths
65. Reduced mortality associated with long-term postmenopausal estrogen therapy
66. Patient-specific decisions about hormone replacement therapy in postmenopausal women